2024
TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL
Lugogo N, Chupp G, Corren J, Israel E, Molfino N, Martin N, Spahn J, Ambrose C. TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL. Annals Of Allergy Asthma & Immunology 2024, 133: s53-s54. DOI: 10.1016/j.anai.2024.08.184.Peer-Reviewed Original ResearchInflammatory biomarker levelsBaseline biomarker levelsBiomarker levelsPost hoc pooled analysisEffect of tezepelumabBaseline to weekLevels of FeNOSerum total IgESerum total IgE.Absolute percentage changeIncreased levelsDouble-blindPlacebo-controlledTezepelumabTotal IgEInflammatory biomarkersParallel-groupUncontrolled asthmaFeNOPatientsPercentage changeBiomarkersPlaceboWeeksBaselineEFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA AND ALLERGIC RHINITIS GROUPED BY BASELINE BLOOD EOSINOPHIL COUNT: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR
WECHSLER M, CHUPP G, ISRAEL E, CASTRO M, BOBER M, LINDSLEY A, SPAHN J, AMBROSE C. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA AND ALLERGIC RHINITIS GROUPED BY BASELINE BLOOD EOSINOPHIL COUNT: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR. CHEST Journal 2024, 166: a4664-a4680. DOI: 10.1016/j.chest.2024.06.2821.Peer-Reviewed Original ResearchProspective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reductionEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, Wechsler M, Hunter G, Lindsley A, Llanos J, Burke L, Chandarana S, Ambrose C. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances In Therapy 2024, 41: 2978-2990. PMID: 38802635, PMCID: PMC11213736, DOI: 10.1007/s12325-024-02889-8.Peer-Reviewed Original ResearchAnnualized asthma exacerbation rateClinically relevant subgroupsEfficacy of tezepelumabBaseline patient characteristicsUncontrolled asthmaClinically relevant subgroups of patientsPatient characteristicsStandard-of-care therapyRelevant subgroups of patientsTezepelumab reduced exacerbationsRelevant subgroupsPlacebo-controlled studyAsthma exacerbation rateSubgroup of patientsReducing asthma exacerbationsBody mass indexPost hoc analysisNSAID sensitivityDouble-blindExacerbation rateTezepelumabSmoking historyPatient subgroupsPlaceboIntroductionMany patientsAsthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024, 133: 302-309. PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burdenClinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study
Lugogo N, Peters A, Chupp G, Wechsler M, Caveney S, Martin N, Parikh B, Ambrose C. Clinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study. 2024, a5251-a5251. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5251.Peer-Reviewed Original ResearchInnate Immune Mechanisms Associated With Exacerbations on Mepolizumab
Wilson G, Liu Q, Gautam S, Knight J, Shelar A, Stewart E, Visness C, Sanders J, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Innate Immune Mechanisms Associated With Exacerbations on Mepolizumab. 2024, a6984-a6984. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6984.Peer-Reviewed Original ResearchAsthma Exacerbation Rates as a Function of Biomarker Levels 4 Weeks After Initiation of Tezepelumab Treatment: An Analysis of the NAVIGATOR Study
Israel E, Chupp G, Lugogo N, Llanos J, Martin N, Martin N, Ambrose C, Jackson D. Asthma Exacerbation Rates as a Function of Biomarker Levels 4 Weeks After Initiation of Tezepelumab Treatment: An Analysis of the NAVIGATOR Study. 2024, a6704-a6704. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6704.Peer-Reviewed Original ResearchImpact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study
Liu M, Chaudhuri R, Chupp G, Heaney L, Lee J, Pilette C, Brusselle G, Alfonso Cristancho R, Zhang L, Howarth P. Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study. 2024, a5376-a5376. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5376.Peer-Reviewed Original ResearchActivated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, PMCID: PMC11305967, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markersMépolizumab est associé à des bénéfices cliniques chez les patients atteints de polypose nasosinusienne, indépendamment de l’utilisation antérieure de corticostéroïdes systémiques
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A, Chachuat L. Mépolizumab est associé à des bénéfices cliniques chez les patients atteints de polypose nasosinusienne, indépendamment de l’utilisation antérieure de corticostéroïdes systémiques. Revue Des Maladies Respiratoires Actualités 2024, 16: 188-189. DOI: 10.1016/j.rmra.2023.11.387.Peer-Reviewed Original ResearchObtention d’une rémission clinique dans l’asthme sévère après un traitement par mépolizumab : résultats de l’étude REALITI-A à 2 ans
Brusselle G, Lougheed D, Canonica G, Munoz-Esquerre M, Heaney L, Price R, Howarth P, Raimondi A, Gardiner F, Chupp G, Welte T, Picaud C. Obtention d’une rémission clinique dans l’asthme sévère après un traitement par mépolizumab : résultats de l’étude REALITI-A à 2 ans. Revue Des Maladies Respiratoires Actualités 2024, 16: 192-193. DOI: 10.1016/j.rmra.2023.11.393.Peer-Reviewed Original Research
2023
Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma
Gautam S, Chu J, Cohen A, Kaur R, Lee S, Wilson G, Liu Q, Gomez J, Rajaveen H, Yan X, Cohn L, Clark B, Chupp G. Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma. Allergy 2023, 78: 3274-3277. PMID: 37874609, PMCID: PMC10842366, DOI: 10.1111/all.15915.Peer-Reviewed Original ResearchEFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchLONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
CHUPP G, LUGOGO N, WECHSLER M, LAWSON K, LINDSLEY A, SPAHN J, AMBROSE C. LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX. CHEST Journal 2023, 164: a9-a14. DOI: 10.1016/j.chest.2023.07.075.Peer-Reviewed Original ResearchLate Breaking Abstract - Clinical remission with mepolizumab in severe asthma: impact of lung function parameters
Oppenheimer J, Carrillo Díaz T, Martínez Moragón E, Sanchez Herrero M, Bañas Conejero D, Chupp G, Price R, Raimondi A, Zhang S, Howarth P, Domingo Ribas C. Late Breaking Abstract - Clinical remission with mepolizumab in severe asthma: impact of lung function parameters. 2023, pa646. DOI: 10.1183/13993003.congress-2023.pa646.Peer-Reviewed Original ResearchiDESC: identifying differential expression in single-cell RNA sequencing data with multiple subjects
Liu Y, Zhao J, Adams T, Wang N, Schupp J, Wu W, McDonough J, Chupp G, Kaminski N, Wang Z, Yan X. iDESC: identifying differential expression in single-cell RNA sequencing data with multiple subjects. BMC Bioinformatics 2023, 24: 318. PMID: 37608264, PMCID: PMC10463720, DOI: 10.1186/s12859-023-05432-8.Peer-Reviewed Original ResearchMepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlaceboDifferences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical featuresIs there a best strategy to prevent asthma exacerbations in inner-city patients with asthma?
Zaeh S, Chupp G, Eakin M. Is there a best strategy to prevent asthma exacerbations in inner-city patients with asthma? Annals Of Allergy Asthma & Immunology 2023, 132: 11-12. PMID: 37433383, PMCID: PMC10774450, DOI: 10.1016/j.anai.2023.07.003.Commentaries, Editorials and Letters